ReviewDrug delivery2020
Fibroin nanoparticles: a promising drug delivery system.
Review in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Live long and active: Polypeptide-mediated assembly of antibody variable fragments.Advanced drug delivery reviews · 2020Pooled it
- Development of Oral pH-Sensitive Eudragit L100-FunctionalizedACS omega · 2026Article
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Development of Resveratrol/Curcumin Dual-Loaded Chitosan/Sericin Hydrogel Films for Wound Healing: A Comparison Of Shrimp- and Crab-Sourced Chitosan.AAPS PharmSciTech · 2026Article
- Engineering complexity into protein-based biomaterials for biomedical applications.Nature reviews. Materials · 2026Article
- The therapeutic efficacy of nanoparticles in the treatment of alzheimer's disease.Acta neurologica Belgica · 2026Review
- Antigen-Containing Silk Nanoparticles: A New Potential as Oral Vaccine Carriers.International journal of nanomedicine · 2026Article
- Bioresponsive gelatin-coated silk fibroin nanoparticles enhance roxadustat therapy in experimental pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- In Vitro Antifungal Activity of Amphotericin B-Encapsulated Silk Fibroin-Chitosan Nanoparticles AgainstPharmaceutics · 2025Article
- Green-Engineered PEI/PVA-Functionalized Silk Fibroin Nanoparticles for Heat-Stable Delivery ofACS omega · 2025Article
- Evaluation of the Cytotoxic Activity of Nanostructured Lipid Carrier Systems for Fatty Acid Amides and Silk Fibroins in Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2025Article
- Silk Fibroin Nanoparticles for Enhanced Cuproptosis and Immunotherapy in Pancreatic Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Silk-based microparticles for the adsorption of methylene blue: formulations, characterization, adsorption study,RSC advances · 2025Article
- Naturally derived hydrogels for wound healing.Therapeutic delivery · 2025Review
- PEGylated Silk Fibroin Nanoparticles for Oral Antibiotic Delivery: Insights into Drug-Carrier Interactions and Process Greenness.ACS omega · 2025Article
- Silk Fibroin Nanoparticles as a Drug Delivery System of 3,3'-Diindolylmethane with Potential Antiobesogenic Activity.ACS omega · 2024Article
- Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer.Materials today. Bio · 2024Article
- Electrospun Silk-ICG Composite Fibers and the Application toward Hemorrhage Control.Journal of functional biomaterials · 2024Article
- The Emerging Role of Silk Fibroin for the Development of Novel Drug Delivery Systems.Biomimetics (Basel, Switzerland) · 2024Review
- Silk Fibroin Materials: Biomedical Applications and Perspectives.Bioengineering (Basel, Switzerland) · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroin is a dominant silk protein that possesses ideal properties as a biomaterial for drug delivery. Recently, the development of fibroin nanoparticles (FNPs) for various biomedical applications has been extensively studied. Due to their versatility and chemical modifiability, FNPs can encapsulate different types of therapeutic compounds, including small and big molecules, proteins, enzymes, vaccines, and genetic materials. Moreover, FNPs are able to be administered both parenterally and non-parenterally. This review summaries basic information on the silk and fibroin origin and characteristics, followed by the up-to-date data on the FNPs preparation and characterization methods. In addition, their medical applications as a drug delivery system are in-depth explored based on several administrative routes of parenteral, oral, transdermal, ocular, orthopedic, and respiratory. Finally, the challenges and suggested solutions, as well as the future outlooks of these systems are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.